Jerome Canady Presents US Medical Innovations at LSI USA ‘23

Transcription

Thank you very much, Dr. Kennedy. I am a physician, surgical oncologist, transplant surgeon, but researcher and scientists and I'm going to present to you a machine with a brain. We are transitioning your medical device to life science company, focusing on advanced therapeutic devices to eradicate cancer with a one's AI smart robotic, cutting edge and disruptive technology. We offer hope, create a state of art technology and dedicated to saving lives. This company started in 2009 for a relay battery manufacturing company with about 1000 square feet and transferred into a vertical manufacturing center to date with FDA 13485 certified UL certified in our translation molecular center ISO 9001. We are a family of structures and background. Our parent company USPPI has 154 partners, and we've raised $60 million to date. We have an experienced management team across the across the arena. What is plasma? Plasma is the fourth state of matter. Everything you do in life is plasma from what you eat, how you drive a car. And we've harnessed the power of plasma and development into treating cancer. Plasma is not this is not blood plasma. This is an energy plasma. And we look at plasma at Kennedy Helios between 24 and 30 degrees Celsius. Versus if you think about lightning effect 30,000 degrees Celsius. Our current product that we've had on the market we've Kennedy hybrid with cuts and seals blood tissue at the same time. We've done over 60,000 procedures. But now we've basically come up with a technology that selectively targets cancer cells without damaging normal tissue with no side effects. Why is this important? Because it's the future of cancer treatment.Why is that important? Because in local recurrence, if you look at women for one example, 280,000 women a year are diagnosed with breast cancer and two thirds of them will have conservative breast surgery. And if you look at the positive margins 34% will have to go re excision and as high as 21% and the recurrence rate is up to 19% in the best of centers around the country. And current treatment today is surgery, radiation, chemotherapy, immunotherapy and target therapy. But we still have this high problem with reoccurrence. Now, we have a bullet to to take care of this problem, cancer tumors located number two is removed with a hybrid plasma technology. It's the cold plasma at the same time in the operating room is sprayed the area and it kills the microscopic tumor cells that the surgeon can't see, and then interrupts the cell cycle of the cancer reducing the viability and causing apoptosis. So a device acting like a drug and how's this work is significantly targets to cancer cells. And so this high frequency electrosurgery combined with the helium gas develops this electromagnetic field. The electromagnetic field develops these we call them species reactive oxygen species or nitrogen species that basically disseminates through the cell membranes causes a translation molecular reaction therefore reacting at the end of a cell death. So hybrid plasma versus cold plasma, as we have on the market today or hybrid plasma technology to the left or cold plasma is 510 K pending. We're looking at our systems about 375,000 with the list price of our disposable about $3,900. Why is this important? Because the addressable market here on the on the hybrid plasmas side and let you search we talked about 6 million procedures a year. Every time you have a tumor or device you have to take the tumor out or you have to have surgery and stop the bleeding, which is a $2.4 million dollar market versus 3.1 billion market for for cancer surgery and not about a 900,000 to a million procedures a year. We have a robust portfolio of intellectual property, over 242 patents filings and pending in 20 plus countries. We have defined the strategic map commercialization clinical trials and the technology portfolio. phase one trial FDA g 191. 190165 that occurred in April, March of 2020 and ended in April 2021. This was phase one trial solid tumors recurrent stage four metastatic approved by FDA the patients might have got radiation chemotherapy, after surgery they received cold plasma and possibly chemotherapy afterwards. Again is a phase one multicenter Open Level prospective control out of Russia University and Sheba Medical Center in Israel. This is one of the procedures performing the cold plasma safety, we looked at tissue temperature if you look at the blue basically tissue temperature at the at the where the area with the cold plasma was 24 degrees compared to the tissue, the body temperature at the time of 36 degrees Celsius. Again, there was no adverse events with the patient that had no effect on the pulse blood pressure and tidal co2 Oh to saturation. It basically we induced it we showed that there was tumor death as well as cessation of tumor growth. And today if you look at we're out to 32 months compared to in green versus the average survival time if these patients did not get cold plasma you can see metastatic colon ovarian you can see the difference. Why is this important to our comp many you might know of Nova cure, which delivers electromagnetic field through a cap. If you look at NOVA cura does the 86 86,000 to 172,000. For complete treatment, it takes 4.3 to 8.2 months, the patient has to have it on their head for 1818 hours a day. Versus this is a one time treatment in the operating room for five to seven minutes, about three about $3,900. So our vision is we have our Helio scope plasma, we developed our own voice control robotic system FDA approved, we've developed we've developed our advanced contour tracking system, our AI optical tumor detection system, as well as well as our robotic optical navigation system to deliver this technology. We have transformed military technology for the treatment of cancer combat can buy the first AI based cold plasma surgical robotic system without the hands of a surgeon.

So it's robotic assisted advance, with our voice control eight seven to eight degrees freedom. It's the advanced contour tracking system. Here's an example of it with our code our system with the plasma range, the patient that surgeon can track out where the robot will go. And this is the marketing product. We also did our or our animal stage where we've developed our first targeted therapy for immune for systemic disease. We also if you think about Alexa, or Google in your house, most hospitals and operating rooms are still 10 years behind. We've developed our Google system we call it Aaron for to integrate the entire operating room and one step beyond that next year we will roll out our meta surgery so they're no longer be where you have to have the nurse pretty much go over to the other side of the room and advance the voltage or the power with time. The surgeon can do it right in front of me at the operating room and then our voice command. If you think about 2001 Odyssey This is where we are today. Vicki move right became moving, Vicki start to demo.

And then again thank you in the middle here is Jeremy. He's the longest living coal plasma recipient 43 months from twice times recurrent sarcoma of his pelvis. He's tumor free for the last 43 months. Thank you.